ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸

AKTS // Aktis Oncology Inc.

FA <GO> NASDAQ RQD COCKPIT → CIK 0002035832 ↗
Health Care • Biotechnology: Pharmaceutical Preparations
$16.85 ▲ +0.03 (+0.18%)
MKT CAP: $937.2M • VOL: 245.7K
AKTS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
LINE ITEM (USD / %)
FY 2025
FILED 2025-12-31
Revenue (Total Sales) $0
YoY Revenue Growth % —
Gross Profit —
Gross Margin % —
Research & Development (R&D) —
Operating Income (EBIT) $0
Operating Margin % —
Net Income (GAAP) $0
EBITDA (Normalized) —
Diluted EPS ($/sh) —
Operating Cash Flow (OCF) —
Capital Expenditures (CapEx) —
Free Cash Flow (FCF) —
FCF Margin % —
Return on Invested Capital (ROIC %) —
Cash & Short-Term Equivalents $37.8M
Total Debt (Short + Long Term) —
Total Stockholders' Equity -$146.1M